U.S. markets open in 7 hours 56 minutes
  • S&P Futures

    4,272.25
    -4.50 (-0.11%)
     
  • Dow Futures

    33,943.00
    -20.00 (-0.06%)
     
  • Nasdaq Futures

    13,473.75
    -19.50 (-0.14%)
     
  • Russell 2000 Futures

    1,989.80
    +0.70 (+0.04%)
     
  • Crude Oil

    88.20
    +0.09 (+0.10%)
     
  • Gold

    1,777.80
    +1.10 (+0.06%)
     
  • Silver

    19.63
    -0.10 (-0.51%)
     
  • EUR/USD

    1.0178
    -0.0002 (-0.02%)
     
  • 10-Yr Bond

    2.8930
    0.0000 (0.00%)
     
  • Vix

    19.90
    +0.21 (+1.07%)
     
  • GBP/USD

    1.2048
    -0.0003 (-0.03%)
     
  • USD/JPY

    134.9970
    -0.0930 (-0.07%)
     
  • BTC-USD

    23,462.30
    -654.04 (-2.71%)
     
  • CMC Crypto 200

    558.08
    -14.73 (-2.57%)
     
  • FTSE 100

    7,515.75
    -20.31 (-0.27%)
     
  • Nikkei 225

    28,972.68
    -250.09 (-0.86%)
     

2seventy bio to Participate in Upcoming Healthcare Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., February 14, 2022--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) announced today that it will present at the following upcoming investor conferences:

  • SVB Leerink 10th Annual Global Healthcare Conference; Fireside chat, Wednesday, February 16, 2022, at 2:20pm ET

  • Cowen Virtual 42nd Annual Healthcare Conference; "Novel Oncology Targets" panel, Monday, March 7, 2022, at 12:50pm ET

Live webcasts of presentations will be available via the Investors and Media section of 2seventy bio’s website at https://ir.2seventybio.com/. A replay of each presentation will be archived on 2seventy bio’s site for 30 days following the event.

About 2seventy bio

Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. We are building the leading immuno-oncology cell therapy company, focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors. Our research and development is focused on delivering therapies that are designed with the goal to "think" smarter and faster than the disease. Importantly, we remain focused on accomplishing these goals by staying genuine and authentic to our "why" and keeping our people and culture top of mind every day.

For more information, visit www.2seventybio.com.

Follow 2seventy bio on social media: Twitter and LinkedIn.

2seventy bio is a trademark of 2seventy bio, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220214005099/en/

Contacts

Investors:
Elizabeth Pingpank, 860-463-0469
elizabeth.pingpank@2seventybio.com

Media:
Victoria Wagner (von Rinteln), 703-599-2868
victoria.wagner@2seventybio.com

Morgan Adams, 774-313-9852
morgan.adams@2seventybio.com